论文信息 - Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype - 字舞流文

Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype

O. Bernard | C. Elie | J. Tamburini | A. Bennaceur-Griscelli | C. Récher | C. Demur | N. Ifrah | P. Mayeux | D. Bouscary | F. Dreyfus | E. Jourdan | M. Attal | S. Malinge | B. Lioure | C. Lacombe | A. Pigneux | F. Witz | V. Bardet | P. Lefebvre | L. D. Costa

[1] Gerhard Ehninger,et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[2] Gerhard Ehninger,et al. Prevalence and prognostic impact of NPM 1 mutations in 1485 adult patients with acute myeloid leukemia ( AML ) , 2006 .

[3] R. Gallagher. Dueling mutations in normal karyotype AML , 2005 .

[4] Stefan Fröhling,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[5] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[6] Guido Marcucci,et al. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics , 2005, Current opinion in hematology.

[7] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.